Respiratorius AB (XSAT:RESP) Debt-to-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Respiratorius AB Debt-to-Asset?

Respiratorius AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr0.00 Mil. Respiratorius AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr0.00 Mil. Respiratorius AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was kr31.02 Mil. Respiratorius AB's debt to asset for the quarter that ended in Dec. 2024 was 0.00.

Respiratorius AB Debt-to-Asset Historical Data

The historical data trend for Respiratorius AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Respiratorius AB Debt-to-Asset Chart

Respiratorius AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

Respiratorius AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Apr22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Respiratorius AB's Debt-to-Asset

For the Biotechnology subindustry, Respiratorius AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Respiratorius AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Respiratorius AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Respiratorius AB's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Respiratorius AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Respiratorius AB's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	31.015
	=	0.00

Respiratorius AB's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	31.015
	=	0.00

Respiratorius AB (XSAT:RESP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Respiratorius AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Respiratorius AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Respiratorius AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Respiratorius AB (XSAT:RESP) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Scheelevagen 2, Medicon Village, Lund, SWE, 223 81

Website

https://www.respiratorius.com

Respiratorius AB develops pharmaceutical drugs to treat the common diseases namely Cancer, Chronic Obstructive Pulmonary Disease (COPD), and asthma as well as better methods for diagnosing cardiovascular diseases. The company's drug candidates includes RCD405, VAL001, RESP2000, RESP3000, RESP9000, and RESP1000.

Respiratorius AB Headlines

No Headlines